Consequences of lifetime isolated growth hormone (GH) deficiency and effects of short‐term GH treatment on bone in adults with a mutation in the GHRH‐receptor gene

Summary Objective  Growth hormone (GH) influences bone mass maintenance. However, the consequences of lifetime isolated GH deficiency (IGHD) on bone are not well established. We assessed the bone status and the effect of 6 months of GH replacement in GH-naive adults with IGHD due to a homozygous mutation of the GH-releasing hormone (GHRH)-receptor gene (GHRHR). Patients and methods  We studied 20 individuals (10 men) with IGHD at baseline, after 6 months of depot GH treatment, and 6 and 12 months after discontinuation of GH. Quantitative ultrasound (QUS) of the heel was performed and serum osteocalcin (OC) and C-terminal cross-linking telopeptide of type I collagen (ICTP) were measured. QUS was also performed at baseline and 12 months later in a group of 20 normal control individuals (CO), who did not receive GH treatment. Results  At baseline, the IGHD group had a lower T-score on QUS than CO (–1·15 ± 0·9 vs.–0·07 ± 0·9, P < 0·001). GH treatment improved this parameter, with improvement persisting for 12 months post-treatment (T-score for IGHD = –0·59 ± 0·9, P < 0·05). GH also caused an increase in serum OC (baseline vs. pGH, P < 0·001) and ICTP (baseline vs. pGH, P < 0·01). The increase in OC was more marked during treatment and its reduction was slower after GH discontinuation than in ICTP. Conclusions  These data suggest that lifetime severe IGHD is associated with significant reduction in QUS parameters, which are partially reversed by short-term depot GH treatment. The treatment induces a biochemical pattern of bone anabolism that persists for at least 6 months after treatment discontinuation.